vs
Side-by-side financial comparison of Actinium Pharmaceuticals, Inc. (ATNM) and Monopar Therapeutics (MNPR). Click either name above to swap in a different company.
Actinium Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($90.0K vs $73.5K, roughly 1.2× Monopar Therapeutics). Monopar Therapeutics runs the higher net margin — -2334.5% vs -5701.1%, a 3366.6% gap on every dollar of revenue. Over the past eight quarters, Monopar Therapeutics's revenue compounded faster (208.9% CAGR vs 41.4%).
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing targeted radiotherapies for oncology patients with unmet medical needs, covering hematologic cancers and solid tumors. Its pipeline uses antibody radiation conjugate technology to deliver precise cancer treatment while minimizing harm to healthy tissue.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. Its lead product candidates address unmet oncology medical needs, serving North American markets and partnering with global healthcare and research institutions to advance its development pipeline.
ATNM vs MNPR — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $90.0K | $73.5K |
| Net Profit | $-5.1M | $-1.7M |
| Gross Margin | — | — |
| Operating Margin | -6324.4% | -2434.5% |
| Net Margin | -5701.1% | -2334.5% |
| Revenue YoY | — | -42.7% |
| Net Profit YoY | 55.6% | 22.0% |
| EPS (diluted) | $-0.16 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $90.0K | — | ||
| Q2 24 | — | $73.5K | ||
| Q1 24 | $927.0K | $82.2K | ||
| Q4 23 | $1.0M | $98.1K | ||
| Q3 23 | $1.1M | $112.3K | ||
| Q2 23 | $461.0K | $128.2K | ||
| Q1 23 | $547.0K | $90.5K | ||
| Q4 22 | $0 | $12.7K |
| Q3 25 | $-5.1M | — | ||
| Q2 24 | — | $-1.7M | ||
| Q1 24 | $-8.7M | $-1.6M | ||
| Q4 23 | — | $-1.8M | ||
| Q3 23 | $-13.3M | $-2.0M | ||
| Q2 23 | $-15.2M | $-2.2M | ||
| Q1 23 | $-11.0M | $-2.4M | ||
| Q4 22 | $-10.6M | — |
| Q3 25 | -6324.4% | — | ||
| Q2 24 | — | -2434.5% | ||
| Q1 24 | -1035.3% | -2097.5% | ||
| Q4 23 | — | -1949.6% | ||
| Q3 23 | -1335.0% | -1840.4% | ||
| Q2 23 | -3393.1% | -1815.8% | ||
| Q1 23 | -2117.7% | -2790.5% | ||
| Q4 22 | — | — |
| Q3 25 | -5701.1% | — | ||
| Q2 24 | — | -2334.5% | ||
| Q1 24 | -935.3% | -1997.5% | ||
| Q4 23 | — | -1849.6% | ||
| Q3 23 | -1235.0% | -1740.4% | ||
| Q2 23 | -3293.1% | -1715.8% | ||
| Q1 23 | -2017.7% | -2690.5% | ||
| Q4 22 | — | — |
| Q3 25 | $-0.16 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-0.31 | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-0.49 | — | ||
| Q2 23 | $-0.58 | — | ||
| Q1 23 | $-0.43 | — | ||
| Q4 22 | $-0.43 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.4M | $6.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.8M | $6.1M |
| Total Assets | $56.2M | $7.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $53.4M | — | ||
| Q2 24 | — | $6.1M | ||
| Q1 24 | $84.1M | $7.8M | ||
| Q4 23 | $76.7M | $7.3M | ||
| Q3 23 | $83.0M | $5.5M | ||
| Q2 23 | $91.3M | $7.2M | ||
| Q1 23 | $94.5M | $5.7M | ||
| Q4 22 | $108.9M | $8.2M |
| Q3 25 | $13.8M | — | ||
| Q2 24 | — | $6.1M | ||
| Q1 24 | $43.9M | $7.5M | ||
| Q4 23 | $36.4M | $5.6M | ||
| Q3 23 | $43.6M | $6.6M | ||
| Q2 23 | $53.1M | $7.8M | ||
| Q1 23 | $57.2M | $8.9M | ||
| Q4 22 | $66.5M | $10.1M |
| Q3 25 | $56.2M | — | ||
| Q2 24 | — | $7.2M | ||
| Q1 24 | $88.4M | $8.9M | ||
| Q4 23 | $81.4M | $7.3M | ||
| Q3 23 | $88.9M | $8.6M | ||
| Q2 23 | $99.1M | $10.3M | ||
| Q1 23 | $102.0M | $11.8M | ||
| Q4 22 | $114.2M | $13.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-1.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-6.3M | — | ||
| Q2 24 | — | $-1.7M | ||
| Q1 24 | $-7.4M | $-1.7M | ||
| Q4 23 | $-47.3M | $-1.5M | ||
| Q3 23 | $-11.1M | $-1.9M | ||
| Q2 23 | $-13.6M | $-2.1M | ||
| Q1 23 | $-15.1M | $-2.3M | ||
| Q4 22 | $-7.8M | $-7.2M |
| Q3 25 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-7.4M | — | ||
| Q4 23 | $-47.5M | — | ||
| Q3 23 | $-11.2M | — | ||
| Q2 23 | $-13.7M | — | ||
| Q1 23 | $-15.2M | — | ||
| Q4 22 | $-7.8M | — |
| Q3 25 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -796.7% | — | ||
| Q4 23 | -4660.3% | — | ||
| Q3 23 | -1037.7% | — | ||
| Q2 23 | -2969.6% | — | ||
| Q1 23 | -2770.2% | — | ||
| Q4 22 | — | — |
| Q3 25 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.2% | — | ||
| Q4 23 | 15.0% | — | ||
| Q3 23 | 2.8% | — | ||
| Q2 23 | 10.2% | — | ||
| Q1 23 | 13.9% | — | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
